Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vixarelimab - Genentech

Next Previous
Drug Profile

Vixarelimab - Genentech

Alternative Names: KPL-716; RG-6536; RO-7622888

Latest Information Update: 24 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen
  • Developer Genentech; Kiniksa Pharmaceuticals
  • Class Antipruritics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Oncostatin M receptor beta subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Interstitial lung diseases; Prurigo nodularis; Pruritus; Ulcerative colitis
  • Phase I Immunological disorders
  • No development reported Atopic dermatitis

Most Recent Events

  • 17 Mar 2025 Phase-I/II clinical trials in Ulcerative colitis (Treatment-experienced) in Germany (SC) (NCT06693908)
  • 18 Nov 2024 Genentech plans a phase I trial for Ulcerative Colitis (Treatment-experienced) (SC, Injection), in February 2025 (NCT06693908)
  • 09 May 2024 Roche plans to file regulatory filing for Idiopathic pulmonary fibrosis, in or after 2027 (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top